The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.
Teny Khachadourian, PharmD Candidate
Advertisement
Articles by Teny Khachadourian, PharmD Candidate
The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
4
Apnimed Submits NDA for AD109 Following Positive Phase 3 Results in Obstructive Sleep Apnea
5